Zealand Pharma A/S American Depositary Shares
ZEAL
ZEAL was delisted on the 29th of September, 2022.
17 hedge funds and large institutions have $88.8M invested in Zealand Pharma A/S American Depositary Shares in 2019 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
31% more funds holding
Funds holding: 13 → 17 (+4)
24% more capital invested
Capital invested by funds: $71.7M → $88.8M (+$17.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$519K |
| 2 |
OMC
Old Mission Capital
Chicago,
Illinois
|
+$293K |
| 3 |
Rockefeller Capital Management
New York
|
+$291K |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$219K |
| 5 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
+$169K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$6.32M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$584K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$19K |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$5.98K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$986 |
ZEAL Hedge Fund Activity: Q4 2019 in Review
17 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Zealand Pharma A/S American Depositary Shares (ZEAL) for Q4 2019, worth a combined $88.8M — up 24% from $71.7M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ZEAL positions and 2 closed out — a net gain of 4 holders — while 4 added to existing stakes and 3 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $519K. The largest seller was Wellington Management Group, cutting an estimated $6.32M.
- 17 institutional investors held Zealand Pharma A/S American Depositary Shares (ZEAL) as of Q4 2019, up from 13 in Q3 2019.
- Funds reported $88.8M of Zealand Pharma A/S American Depositary Shares stock for Q4 2019, up 24% quarter-over-quarter.
- 6 funds opened new Zealand Pharma A/S American Depositary Shares positions in Q4 2019 and 2 closed out, a net change of +4 holders.
- The largest Zealand Pharma A/S American Depositary Shares buyer in Q4 2019 was Renaissance Technologies, an estimated $519K added.
- The largest Zealand Pharma A/S American Depositary Shares seller in Q4 2019 was Wellington Management Group, an estimated $6.32M sold.
Based on aggregated 13F filings for Q4 2019.